Recombinant @entity1 @entity1841 and XXXX : a retrospective cohort study.

@entity1 @entity788 @entity1841 @entity6 @entity5 @entity6861
PURPOSE: To assess whether use of recombinant @entity1 @entity1841 (rhBMP-2) during lumbar spinal fusion surgery affects subsequent risk of @entity788 . METHODS: Using US Medicare claims data, we performed a retrospective cohort study of @entity1 who underwent lumbar spinal fusion surgery between October 2003 and December 2005. The study population, all >66 years, was identified from procedure codes for lumbar fusion. Claims for a @entity6861 ( @entity6861 ) served as a proxy for rhBMP-2 exposure (another @entity6861 product shared the same code). @entity788 was identified from claims indicating this diagnosis and @entity5 -specific therapy. We used Cox proportional hazard regression to estimate hazard ratios (HRs) and 95%CIs. RESULTS: Of the 93,654 @entity1 in the study, the mean age was 75 years, and 16.5% had claims for @entity6861 . During a mean 1.4 years of follow-up, 91 @entity1 were diagnosed with @entity788 (eight in the @entity6861 - and 83 in the non- @entity6861 cohort). Consistent with previous research, @entity788 was associated with older age, male gender, black race, and @entity6 . Compared to those who did not receive @entity6861 , @entity1 exposed to @entity6861 were not at increased risk of @entity788 (adjusted HR=0.70, 95%CI: 0.34-1.45). A chart review substudy validated the exposure measure; 52/55 @entity1 with claims for @entity6861 received rhBMP-2. CONCLUSIONS: In this large study of elderly @entity1 who underwent lumbar fusion surgery, exposure to @entity6861 was not associated with an increased risk of @entity788 .
